胎盘功能障碍与胎儿生长受限:基础研究与临床创新的桥梁OA

Fetal growth restriction(FGR)is a significant clinical condition affecting neonatal prognosis,especially prevalent in regions with limited medical resources.This condition not only significantly increases the risk of perinatal mortality but is also closely associated with long-term neurodevelopmental disorders and cardiovascular metabolic diseases.From a pathogenic perspective,placental dysfunction is the core link of FGR,involving multiple pathological processes such as vascular dysregulation,metabolic disorders,and inflammatory responses.In terms of clinical diagnosis and treatment,current approaches mainly rely on a series of ultrasound monitoring,combined with hemodynamic indicators such as umbilical artery blood flow spectrum and uterine artery pulsatility index for comprehensive assessment.Treatment remains challenging,with a lack of specific drugs,and mainly involves nutritional support and individualized obstetric management plans.Currently,precision medicine offers new opportunities for the diagnosis and treatment of placenta-originated FGR.Therefore,through a systematic literature review,a deeper understanding of the pathogenesis and clinical management of placenta-originated FGR can be achieved.This understanding,on one hand,helps establish a standardized prenatal monitoring system and promotes precise diagnosis;on the other hand,it facilitates the establishment of a multidisciplinary collaborative diagnosis and treatment model,providing a basis for individualized treatment.